Purpose: Smad4 loss is highly related to poor prognosis and decreased patient survival in oral squamous cell carcinoma (OSCC), suggesting that agents that target both Smad4-mutat ed and Smad4 wild-type cells could treat OSCC more effectively. Disulfiram (Dsf) has anticancer activity through a variety of mechanisms, including inhibition of epithelialmesenchymal transition (EMT). It remains unclear whether Dsf has the same effect on Smad4-mutated and Smad4 wild-type OSCC or not and what mechanism is involved. Methods: Effect of Dsf on TGFβ 1 -induced EMT in CAL27 (Smad4 mutation) and SCC25 (Smad4 wild-type) cells were evaluated through analyzing changes in morphology, expression of EMT markers, and migration and invasion of cells. The ERKpathway inhibitor U0126 was used to confirm TGFβ-ERK-Snail pathway-mediated cell behavior. Dsf's effects on tumor growth and metastasis in vivo were examined through a subcutaneous xenograft mouse model and an intravenous tumor mouse model. Results: Dsf inhibited TGFβ 1 -induced EMT through suppression of morphological change, EMT-marker expression, and cell migration and invasion in both CAL27 and SCC25. Phosphorylation of ERK and expression of Snail were blocked by Dsf treatment. Like Dsf, U0126 had a similar effect on EMT of CAL27 and SCC25. Dsf also reduced tumor growth and metastasis in vivo, accompanied by decreased expression of EMT markers in tumors. Conclusion: These results indicated that Dsf inhibited EMT of OSCC in vitro and in vivo independently of Smad4 through suppression of the TGFβ-ERK-Snail pathway, suggesting the broad-spectrum anticancer potential of Dsf for clinical use against OSCC.
were newly diagnosed with cancer of the lip and oral cavity, which makes oral cancer a leading cause of cancer death, especially among men in South Asia. 5 Numerous studies have demonstrated that epithelialmesenchymal transition (EMT) is implicated in promoting carcinoma invasion and metastasis in multiple kinds of cancer, 6 including oral cancer. 7 EMT is a highly conserved cellular program in which polarized immotile epithelial cells convert to motile mesenchymal cells. 8 It is a fundamental process for morphogenesis during embryonic development, tissue remodeling and wound healing, which involves a variety of signaling pathways (eg, TGFβ, Wnt, Notch) and is characterized by downregulated expression of epithelial proteins, such as E-cadherin, and upregulated expression of mesenchymal protein, such as vimentin. 9 Furthermore, it has been proved that decreased E-cadherin and increased vimentin are closely associated with recurrence and death in OSCC patients. 10 Also, transcription factors, such as Snail, Slug, ZEB1, ZEB2, Twist1, and Twist2, responsible for suppressing E-cadherin expression, are related to EMT.
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As a genetic disease, cancer usually accumulates genetic and epigenetic aberrations, 12 which cause heterogeneity of cancer, leading to worse clinical outcomes. Smad4 is a strong tumor suppressor, the loss or inactivation of which is common in tumorigenesis. 13 Loss of chromosome 18q, a region encoding Smad4, is commonly found in human head and neck SCC (HNSCC), 14 which is associated with decreased survival rates.
Research on Smad4 expression in human HNSCC showed that 86% of tumors and 67% of adjacent nonmalignant mucosa had >50% Smad4 reduction 15 and a Smad4-knockout mouse model showed increased HNSCC susceptibility. 15 As an important signaling molecule in the TGFβ pathway, Smad4 plays an ambiguous role in TGFβ-induced EMT, dependent on cell type. In NMuMG mouse mammary gland epithelial cells, Smad4 loss abolished TGFβ-induced EMT, 16 while in Colo-357 pancreatic tumor cells, Smad4 was dispensable in TGFβ-induced EMT. 17 However, it is still unknown whether Smad4 is essential for TGFβ-induced EMT in OSCC. Disulfiram (Dsf), which has been used for alcohol dependence since the 1940s, 18 has shown anticancer activity for four decades and been widely researched. 19 Dsf plays its anticancer role through blockage of proteasome activity, 20 induction of cell apoptosis, 21 inhibition of invasion and angiogenesis, 22 suppression of stem cell-like properties, 23 and reduction of drug resistance. 24 Besides acting on cancer cells, Dsf can affect tumor stromata, such as macrophages, resulting in disturbed cancer progression. 25 In the field of metastasis, research has shown that Dsf suppresses invasion of tumor cells through inhibition of MMP2 and MMP9 activity. 26 In addition, it has been reported that Dsf inhibited TGFβ-induced EMT in breast cancer cells and tumor growth in a xenograft model. 27 Although Dsf's anticancer activity has been proved in a variety of cancers, previous studies ignored the existence of different mutants in cancer. It remains unclear whether Dsf has the same effect on Smad4-mutated and Smad4 wild-type OSCC cells or not and what mechanism is involved.
In this study, we discovered that Dsf inhibited EMT both in Smad4-mutated and Smad4 wild-type OSCC cells. This inhibition of EMT was attributed to downregulation of the TGFβ-ERK-Snail pathway independently of Smad4, leading to decreased tumor growth and reduced metastasis in vivo.
Methods Reagents
Dsf and U0126 were purchased from MCE (USA) and dissolved in DMSO. TGFβ 1 was purchased from Proteintech (USA) and dissolved in 4 mM HCl containing 0.1% endotoxin-free human serum albumin to a concentration of 0.5-1.0 mg/mL. Primary antibodies against E-cadherin, vimentin, and GAPDH were purchased from Proteintech, antibodies to ERK and p-ERK from Cell Signaling Technology (USA), antibodies to Snail from Abcam (UK), and antibodies to Ki67 from Santa Cruz Biotechnology (USA).
Cell culture
The human OSCC cell lines CAL27 and SCC25 were obtained from Nanjing Keygen Biotech (China). These cells were grown in DMEM (Thermo Fisher Scientific, USA) containing 10% FBS (Biological Industries, Israel) with 100 U/mL penicillin and 100 μg/mL streptomycin (HyClone, USA) in a 37°C humidified incubator containing 5% CO 2 .
Cytotoxicity assay
Cells were seeded at 10 4 /well in a 96-well plate overnight, followed by incubation with Dsf at different concentrations for 24 hours. Then, 10 μL CCK8 solution was added for 2 hours at 37°C. OD 450 values were obtained with a microplate reader (Bio-Rad, USA). Percentage cell viability was calculated compared to control wells without Dsf.
Cell-apoptosis analysis
Apoptosis analysis was performed with an annexin V APC apoptosis-analysis kit (Tianjin Sungene Biotech, China). Briefly, cells from different groups were collected, washed with cold PBS, resuspended in 100 μL of binding buffer. Annexin V APC (5 μL) and 5 μL propidiumiodide solution were added to the cell solution for 15 minutes at room temperature, followed by flow-cytometry analysis.
Cell-cycle assessment
Cells from different groups were collected before fixing them with cold ethanol for 1 hourr at room temperature. Cells were washed with cold PBS, followed by resuspension in 0.5 mL propidium iodide-RNase staining solution (Tianjin Sungene Biotech, China). After incubation for 30 minutes at room temperature, samples were analyzed by flow cytometry.
Immunofluorescence staining
Cells were cultured in six-well plates and treated with different drugs. After being washed with PBS twice, cells were fixed with 4% paraformaldehyde for 20 minutes at room temperature. Then, they were permeabilized with 0.1% Triton X-100 and blocked with 5% BSA, followed by incubation with primary antibody over night at 4°C. After incubation with Cy3-labeled goat antirabbit IgG antibody (Proteintech) for 1 hour at room temperature in the dark, cells were counterstained with DAPI. Images were collected using fluorescence microscopy (Olympus, Japan).
Western blot
Cells were washed with cold PBS twice and lysed in RIPA buffer containing protease inhibitor and phosphatase inhibitor. Then, the lysate was centrifuged for 20 minutes and the supernatants retained. Protein samples were separated by 8%-12% SDS-PAGE and transferred onto polyvinylidenedifluoride membranes. After being blocked with 5% BSA in TBST, membranes were incubated with primary antibodies overnight at 4°C and subsequently incubated with secondary antibodies (Proteintech). The signals were detected with an enhancedchemiluminescence-detection reagent. Results were normalized to the internal control -GAPDH.
In vitro migration and invasion assays
The upper chamber of the transwell (Corning Costar, USA) was coated with Matrigel (BD, USA) for invasion assays and without Matrigel for migration assays. Cells were pretreated with Dsf for 24 hours before simulation of TGFβ1 and Dsf for 6 days, then seeded in the upper chamber (5×10 4 /well) with DMEM while supplying DMEM containing 10% FBS in the lower chamber. After incubation for 24 hours, cotton swabs were used to remove cells in the upper chamber and invaded cells that had traversed to the reverse side of the membrane were fixed with 4% paraformaldehyde and stained with gentian violet.
Animal experiments
Male BALB/c nude mice 4-6 weeks old (Beijing Vital River Laboratory Animal Technology, China) were housed in pathogen-free conditions. For the subcutaneous tumor model, CAL27 cells (5×10 6 /100 μL DMEM per mouse) were subcutaneously injected in the right flank of mice. When the average tumor volume had reached 100 mm 3 , the mice were randomly divided into two groups, which were treated with vehicle (saline only) or Dsf (50 mg/kg) twice a week by intragastric administration for 38 days. Tumor volume was measured at the same time. For the intravenous tumor model, CAL27 cells were pretreated with Dsf and TGFβ1 in vitro, then 5×10 6 cells/100 μL DMEM per mouse)
were injected into the caudal vein, followed by 2 months' housing. Then, these mice were killed, and tumors and organs collected were fixed, paraffinembedded, sectioned, and stained with H&E. Animal experiments were conducted according to the animal care guidelines of Jilin University. Animal use in this study was approved by the Institutional Animal Care and Use Committee of Jilin University, Changchun, China (permit SYXK 2018-0006).
Immunohistochemistry
Immunohistochemistry was performed with formalinfixed, paraffin-embedded tumor-sample sections. After being deparaffinized and rehydrated, sections were stained with primary antibodies for 2 hours at room temperature. Then, sections were incubated with biotinylated secondary antibody, followed by a horseradish peroxidase-conjugated streptavidin-biotin complex. After developqment in diaminobenzidine, these sections were observed under light microscopy.
Statistical analysis
All in vitro experiments were repeated at least three times. All data are expressed as means ± SEM. Comparisons among multiple group were made by one-way ANOVA followed by Tukey post hoc analysis. P<0.05 was used for statistical significance.
Results

Dsf suppressed TGFβ 1 -induced EMT in OSCC cells
TGFβ 1 was used to induce EMT in OSCC CAL27 (Smad4-mutated) and SCC-25 (Smad4 wild-type) cells in vitro. 28 To eliminate the interference of cell death and inhibition of cell proliferation in TGFβ 1 -induced EMT, we initially determined noncytotoxic Dsf concentration by CCK8 assay ( Figure S1 ). A range of concentrations (5 μM, 10 μM, and 20 μM) were chosen to be used in following experiments. Indeed, these concentrations of Dsf had no influence on cell apoptosis or the cell cycle ( Figures S2 and S3 ). Morphological change, which is indicative of EMT, was initially observed ( 
Dsf inhibited TGFβ-ERK-Snail pathway in OSCC cells independently of Smad4
TGFβ can induce EMT through both Smad-dependent and Smad-independent pathwas. Smad4 loss disturbs the Smad-dependent pathway. Based on the results in Figures 1 and 2 , showing Dsf blocked TGFβ 1 induced EMT in both Smad4-mutated CAL27 and Smad4 wild-type SCC25 cells, we believe a Smadindependent pathway was involved in the inhibitory effect of Dsf on EMT. Phosphorylation of ERK was necessary in TGFβ 1 -induced EMT in murine mammarygland epithelial cells. Therefore, we checked the change in ERK activation by Western blot. Results showed that TGFβ 1 significantly promoted phosphorylation of ERK in 15 minutes, then phosphorylation decreased, while this effect was blocked by Dsf ( Figure 3, A and D) . We also analyzed downstream signaling of ERK, which is responsible for TGFβ 1 -induced EMT. As an important transcriptional factor in EMT, Snail has been reported to be upregulated by ERK and TGFβ. As shown in Figure  1 , C and G , TGFβ 1 stimulated the expression of Snail, but Dsf suppressed this promoting effect. All these results were similar in Smad4-mutated and Smad4 wildtype OSCC cells.
To further make sure that Dsf inhibited EMT through inhibition of the TGFβ-ERK-Snail pathway, U0126, a chemical inhibitor of MEK1/2-upstream activator of ERK, was used. Our data showed that U0126 suppressed the TGFβ-ERK-Snail pathway, demonstrated by reduced expression of p-ERK and Snail (Figure 3, C and F) . Corresponding with the effect of Dsf on EMT, U0126 treatment resulted in increased expression of E-cadherin and decreased levels of vimentin ( Figure 3, C and F) . Also, U0126 obviously blocked TGFβ 1 -induced migration and invasion (Figure 3, B and E) . These results provide solid evidence of Dsf's anti-EMT activity through the TGFβ-ERK-Snail pathway independently of Smad4.
Dsf suppressed metastasis in vivo
EMT is highly associated with tumor metastasis, so we investigated antimetastasis activity of Dsf in vivo. CAL27 cells were pretreated with TGFβ 1 for 6 days in vitro to trigger EMT or pretreated with Dsf (20 μM) for 24 hours before TGFβ 1 stimulation to inhibit EMT in vitro, then intravenously injected into nude mice through the caudal vein. Surprisingly, we found macroscopic subcutaneous tumors on buttocks in the control and TGFβ 1 groups, with tumors in the TGFβ 1 group larger than the control group, while only one mouse (n=3) was found with macroscopic tumors in the Dsf group, which was much smaller ( Figure 4A ). Results from immunohistochemistry of these tumors showed that pretreatment with TGFβ 1 caused stronger expression of vimentin and Snail compared with the control group, whereas this upregulation was suppressed by Dsf pretreatment ( Figure 4C) . A large number of macroscopic metastatic nodules on the lung were observed in the TGFβ 1 group, despite few megascopic metastases in the control and Dsf-treatment groups ( Figure 4B ). H&E staining was performed to check intrapulmonary metastasis further. Metastatic nodules were distributed sporadically in the control group, while widely distributed in the TGFβ group and scarcely distributed in the Dsf group ( Figure 4B ). Taken together, these results indicate that Dsf inhibited OSCC metastasis on account of TGFβ 1 induction. 
Dsf inhibited OSCC growth
Finally, to investigate the effect of Dsf on OSCC growth, we established a subcutaneous tumor model in BALB/c nude mice with CAL27 cells. As shown in Figure 5 , A and B, compared with the control group, tumor volume in the Dsf-treated group was suppressed markedly. To evaluate the proliferation status of tumors, we performed immunohistochemical staining of Ki67 ( Figure 5C ). Ki67 expression was inhibited significantly in the Dsftreatment group, which indicated Dsf anticancer activity in OSCC. The EMT status of these tumors was also investigated. We found obvious expression of vimentin and Snail at the infiltrative border in the control group, while expression of these EMT markers was blocked when mice were administered Dsf ( Figure 5C ), suggesting that Dsf can inhibit tumor growth and EMT in vivo. 
Discussion
As a key mediator in canonical TGFβ signaling, Smad4 was firstly identified as tumor suppressor in the pancreas. 29 Reduced expression of Smad4 was found in five OSCC cell lines compared with normal oral keratinocytes. 30 In an immunostaining study of 108 OSCC tissue samples, Smad4 loss was as high as 61.12%, and this loss was significantly associated with more advanced tumor features, such as poorly differentiated tumors, lymph-node metastasis, and decreased survival rates. 31 These observations suggest that Smad4 loss or reduction is a common event in OSCC and adverse to OSCC therapy. Therefore, finding a drug that can target Smad4-mutated and Smad4 wild-type OSCC is meaningful for better treatment of patients.
Although the anticancer effect of Dsf has been known in numerous cancers for many years, 19 very little is known about this drug's activity on Smad4-mutated or Smad4 wild-type OSCC. Therefore, we used the Smad4-mutant OSCC cell line CAL27 to establish a subcutaneous xenograft nude mouse model and examined the anticancer effect of Dsf on OSCC with this model. Consistently with previous studies, we found that Dsf obviously inhibited tumor growth. Previous research has also demonstrated that Dsf blocks lung metastasis of human hepatocellular carcinoma cells and liver metastasis of human breast cancer cells in nude mice. As such, we examined the antimetastasis effect of Dsf on OSCC in in an intravenous tumor mouse model. As expected, we found that Dsf suppressed OSCC lung metastasis in vivo. Uncommonly, we observed subcutaneous metastasis at the buttock in the intravenous tumor mouse model. This might be attributable to the specific subcutaneous microenvironment where CAL27 cells prefer to colonize. It has been reported that patients with SCC can suffer subcutaneous metastasis, although this metastasis is relatively rare. [32] [33] [34] Also, subcutaneous metastasis is usually associated with rapid progression of cancer. Indeed, in our experiment, the TGFβ group had much bigger subcutaneous metastatic tumors compared with the control and Dsf groups, while the Dsf group had only one small subcutaneous metastatic tumor. In conclusion, our data indicate that Dsf is effective in inhibiting highly malignant OSCC growth and metastasis.
EMT is an important progress implicated in cancer metastasis. 6 Indeed, we found downregulated expression of the EMT markers vimentin and Snail when Dsf inhibited OSCC metastasis in vivo, suggesting that EMT is involved in the antimetastasis activity of Dsf. As such, we investigated the effect of Dsf on EMT in OSCC cells in vitro. In order to figure out whether the mutation of Smad4 influenced the activity of Dsf in OSCC, we chose Smad4-mutated (CAL27) and Smad4 wild-type (SCC25) OSCC cells. 28 EMT is characterized by loss of epithelial cell polarity and acquisition of mesenchymal morphology, accompanied by cell migration, invasion, metastasis, and chemotherapeutic resistance. 8, 9 The anti-EMT effect of Dsf has been proved in hepatocellular carcinoma and breast cancer. 27, 35 In line with previous reports, our results showed that Dsf suppressed EMT in OSCC, demonstrated by recovery of epithelial morphology, decreased migration, and invasion potential, and reduced expression of vimentin, independently of Smad4. These findings indicated that Dsf has a broad-spectrum anti-EMT effect in multiple cancers and this effect is unaffected by Smad4 mutation, suggesting most human OSCC tumors will be sensitive to Dsf treatment, even though 61.12% of them are Smad4-mutated, portending powerful clinical translational potential for our findings.
Multiple signaling pathways participate in EMT, among which the TGFβ-signaling pathway has been best studied. 9 TGFβ promotes EMT through Smaddependent and Smad-independent pathways. 9 Smad4, the loss of which abrogates the Smad-dependent TGFβ pathway, combines with phosphorylated Smad2/ 3 after binding of TGFβ to its receptor, then translocates into nuclei to regulate the expression of transcriptional factors implicated in the initiation of EMT. 36 Our results showed that Dsf can inhibit EMT without the influence of Smad4 mutation, suggesting a Smad-independent pathway is involved in the anti-EMT activity of Dsf. As one of the Smad-independent TGFβ pathways, the ERK pathway plays a vital role in cancer progression. Activation of this pathway contributes to growth promotion in pancreatic cancers and progression in undifferentiated carcinomas when Smad4 is abolished 37, 38 and was required in TGFβ 1 -induced EMT in murine mammary-gland epithelial cells. 39 Consistently with previous reports, we found that TGFβ 1 induced phosphorylation of ERK in both Smad4-mutated and Smad4 wild-type OSCC cells. The kinetics of ERK phosphorylation by TGFβ induction vary by cell type and culture condition. Activation with delayed response in some cell lines may result from Smad-dependent transcription responses, but rapid activation (5-15 minutes) in other cases suggests independence of transcription. 40, 41 Like the latter, in our research TGFβ 1 induced ERK phosphorylation rapidly at 5 minutes, followed by the most prominent at 15 minutes, further suggesting that this activation of ERK is independent of Smad4. Snail is an important transcriptional factor in EMT, which can bind to adjacent E-boxes in genes encoding epithelial markers, such as E-cadherin, CAR, and occludin, leading to gene repression. 42 The ERK pathway participates in the activation of the Snail minimal promoter, 43 by which activation of ERK promotes breast cancer cell migration and invasion. 44, 45 Our results showed that the suppression effect of Dsf on the TGFβ-ERK-Snail pathway in EMT without Smad4 involvement and that inhibition of the TGFβ-ERK-Snail pathway by U0126, a chemical inhibitor of MEK1/2, the upstream activator of ERK, resulted in blocked EMT, consistent with the effect of Dsf. These findings testified that Dsf inhibited EMT in OSCC by targeting TGFβ-ERK-Snail pathway, rising above Smad4. Numerous evidence has proved that the ERK-signaling pathway promotes cell proliferation and cancer metastasis. 46 In our experiment, we observed that Dsf suppressed ERK phosphorylation, which may have contributed to Dsf's inhibition effect on tumor growth and metastasis in vivo.
Conclusion
Dsf triggered an inhibitory effect on EMT in OSCC, in accordance with reduced migration and invasion in vitro, as well as decreased tumor growth and metastasis in vivo. The Smad4-independent pathway TGFβ-ERK-Snail pathway was found to play an essential role in the Dsf-induced restraining of OSCC EMT. Based on these findings, more research is needed to evaluate the anti-EMT effect of Dsf in other gene-mutated cancers and relevant preclinical models, promoting its clinical use against human OSCC.
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